Skip to content

Partner Perspective

Give Your Patients More Time: Early Alzheimer’s Intervention Now Available at New Mexico Cancer Center
A Partner Perspective from Dr. Barbara McAneny
Branded Content Sponsored by NMCC

New Mexico Cancer Center has started an Alzheimer’s program – an initiative that may seem unconventional at first glance but is rooted in logic and patient need. With an on-site neurologist – Dr. Timothy Ownbey – PET and MRI imaging, a full-service lab and an established outpatient infusion center, we are uniquely positioned to deliver comprehensive Alzheimer’s care – efficiently and affordably.

This program grew out of a very personal diagnosis within my family and has driven me to do what I can to help others facing this devastating disease. And it likely affecting your patients as well. Nationally, 7 million people are living with the devastating disease, and 12 million people are serving as caregivers.

New disease-modifying therapies can now slow the progression of Alzheimer’s, offering patients a chance to maintain independence and quality of life and easing the burden on caregivers. Early detection is essential for these treatments to be effective, yet what I have seen firsthand is that timely diagnosis was a challenge. Even being part of this medical community, I experienced frustration trying to secure the needed appointments for a family member. So imagine what patients feel when they face long waits to see a neurologist or lack a primary care provider to initiate the diagnostic process.

Our approach removes these barriers. Patients can come to us directly or through your referral. If they don’t have a PCP, we can connect them with one of our advanced practice clinicians. We then facilitate comprehensive workups, including:

• Blood tests to rule out reversible causes of cognitive decline
• APOE genetic testing
• MRI to rule out untreatable microinfarct dementia
• Vizamyl PET imaging, the gold standard for Alzheimer’s diagnosis

The new drugs have risks such as micro bleeds in the brain, but randomized controlled studies have showed that they can slow the progression to provide up to a year or more good quality brain function.

The Alzheimer’s Association has noted that 92% of Americans would be willing to take a treatment that slowed the progression of Alzheimer’s if they knew that they were preserving good quality life.

Once testing is complete, patients meet with Dr. Ownbey for diagnosis and care planning. If appropriate, treatment is provided through our outpatient infusion center at significantly reduced cost compared to hospital settings - an important consideration for our largely Medicare population.

We’ve partnered with the New Mexico chapter of the Alzheimer’s Association to offer robust caregiver and patient support services. Most importantly, we ensure care is delivered in a setting that is familiar, friendly, and accessible - something that can make all the difference for patients with cognitive impairment.

At NMCC, we believe our resources shouldn’t serve only oncology patients. With capacity in our imaging and infusion services, we’re expanding our mission: delivering 21st-century care in a welcoming environment at a cost patients can afford.

We welcome your referrals and are happy to coordinate directly with your office. Together, we can help more New Mexicans access the timely Alzheimer’s care they deserve.

Untitled design (72)

This article is part of a branded content partnership with New Mexico Cancer Center and does not constitute a clinical endorsement by GAMA. Views expressed are those of the author.

About the Author

Untitled design (70)

Barbara L. McAneny, MD
Medical Oncologist, CEO

Specialties: Medical Oncology, Hematology

Position: Full Time Practice, CEO of NMOHC and NMCC (Founding Partner of NMOHC)

Practice Locations: Albuquerque, Gallup

Joined NMOHC: 1985

Medical School: University of Iowa, 1977

Residency: Internal Medicine, University of Iowa, 1980

Fellowship: Oncology & Hematology, University of New Mexico, 1983

Board Certification: Internal Medicine, Medical Oncology, Hematology

Specialty Society Fellowship Recognition: Fellow of the American College of Physicians (FACP) and Master of the American College of Physicians (MACP).

Experience & Interests: Dr. McAneny is CEO of New Mexico Oncology Hematology Consultants, LTD and the past President of the New Mexico Cancer Center Foundation. She has lived in Albuquerque since 1980.

Dr. McAneny is active in organized medicine and advocacy. She was the 1989 President of the Greater Albuquerque Medical Association and was President of the New Mexico Medical Society in 2000. She served a four-year term on the Practicing Physicians Advisory Council for the Centers for Medicare and Medicaid Services, on the AMA Council of Medical Service, and the American Society of Clinical Oncologists (ASCO) Board of Directors and their Clinical Practice committee. She is a member and Past-Chair of the Board of Trustees of the American Medical Association. In June of 2017, Dr. McAneny was elected by the AMA House of Delegates as President Elect of the AMA.

team building
Scroll To Top